Descripción del brote de poliomielitis en la Argentina de 1971 / Description of the 1971 poliomyelitis outbreak in Argentina

La poliomielitis es una enfermedad de antigua data que afecta exclusivamente a los humanos. Sus secuelas de parálisis se encuentran ya documentadas en escritos del antiguo Egipto. Es producida por el poliovirus y se transmite por vía fecal-oral. Uno de cada doscientos niños infectados sufre un ataque vírico a las neuronas motoras del sistema nervioso central, que deja como secuela una parálisis flácida muscular. En la Argentina, las últimas epidemias de poliomielitis ocurrieron entre 1955 y1957, en 1971 y en 1983. La epidemia de 1953 registró 2.700 casos, mientras que en la de 1956 hubo 6.490 casos, con una tasa de mortalidad del 33,7%. Durante 1971, 46 pacientes fueron internados con diagnóstico de poliomielitis en las salas que dependían de la cátedra de Enfermedades Infecciosas de la Facultad de Ciencias Médicas de la Universidad de Buenos Aires, en el predio del Hospital Francisco Javier Muñiz. La cohorte estaba compuesta por 26 varones y 20 mujeres. Hemos realizado una revisión de las historias clínicas de aquellos pacientes, obrantes en el archivo de la cátedra. (AU)

Poliomyelitis is a human disease of ancient origin. Evidence of sequelae of paralysis is documented in ancient Egyptian writings. It is caused by the poliovirus and is transmitted through the fecal-oral route. One out of 200 infected children suffers a viral attack on the central nervous system´s motor neurons, which results in flaccid muscle paralysis. In Argentina, the last polio epidemics occurred between 1955 and 1957, in 1971 and in 1983. The 1953 poliomyelitis epidemic reported a total of 2,700 cases, while in the 1956 outbreak 6,490 cases were recorded with a mortality rate of 33.7%. In 1971, 46 patients were diagnosed with poliomyelitis and admitted to the wards of the Department of Infectious Diseases at the Faculty of Medical Sciences, University of Buenos Aires, located in the Javier Muñiz Hospital. The cohort consisted of 26 men and 20 women. We reviewed the medical records of those patients, recorded in the Department´s archive. (AU)

Vacinação contra poliomielite no Brasil de 2011 a 2021: sucessos, reveses e desafios futuros / Vaccination against poliomyelitis in Brazil from 2011 to 2021: successes, setbacks, and challenges ahead

Resumo A queda de coberturas vacinais (CV) na infância, entre elas a da poliomielite, vem se tornando uma preocupação sanitária. O objetivo foi analisar a tendência temporal das coberturas das três doses da vacina contra a poliomielite nos primeiros 12 meses de vida entre 2011 e 2021, com destaque na pandemia de COVID-19, além de mapear as CV no Brasil. Foi realizado um estudo ecológico com técnicas de série temporal interrompida (STI) e análise espacial, a partir dos dados do Sistema de Informação do Programa Nacional de Imunização. A tendência da CV foi ajustada pelo estimador de variância de Newey-West, segundo as unidades federadas e o Índice de Privação Brasileiro. A distribuição da CV foi estimada por modelos bayesianos e os aglomerados espaciais pelos índices de Moran global e local, identificando áreas de menor cobertura nas Regiões de Saúde. Observa-se perda da CV ao longo do período em todas as regiões do país, sendo maiores no Norte e no Nordeste e se acentuando durante a pandemia. As maiores quedas foram identificadas em estados e regiões de saúde com maior vulnerabilidade social. A queda na CV mostra que o risco de reintrodução do vírus selvagem é iminente e os desafios precisam ser enfrentados com o fortalecimento do Sistema Único de Saúde.

Abstract The drop in childhood vaccination coverage (VC), including poliomyelitis, has become a health concern. The objective was to analyze the temporal trend of coverage of the three doses of the polio vaccine in the first 12 months of life between 2011 and 2021, in addition to mapping vaccination coverage in Brazil, including the COVID-19 pandemic period. An ecological study was carried out using interrupted time series (STI) techniques and spatial analysis, with data from the National Immunization Program Information System. The VC trend was adjusted by the Newey-West variance estimator according to the federated units and the Brazilian Deprivation Index. The VC distribution was estimated by Bayesian models and the spatial clusters by the global and local Moran index, identifying areas of lower coverage in the health regions. There was a reduction in the VC over the period in all regions, being more pronounced in the North and Northeast regions and during the Covid-19 pandemic. The biggest drops were identified in states and health regions with greater social vulnerability after 2019. The drop in VC shows that the risk of reintroduction of the wild virus is imminent and the challenges need to be faced with the strengthening of the Brazilian Health System (SUS).

Temporal and spatial distribution of polio vaccine coverage in Brazil between 1997 and 2021 / Distribuição temporal e espacial da cobertura vacinal contra poliomielite no Brasil entre 1997 e 2021

ABSTRACT Objective: To analyze the temporal and spatial distribution of polio vaccine coverage in Brazilian states. Methods: An ecological time series study was conducted using data from the National Immunization Program Information System. The analyzed period was from 1997 to 2021. Joinpoint software was used to calculate the annual percentage change and average annual percentage change through regressions. QGIS 3.10.7 software was used to construct thematic maps. GeoDa 1.20.0.10 software was used to estimate spatial autocorrelation using the Global Moran's Index and Local Moran's Index. Results: National vaccine coverage in 1997 was 89.27%, decreasing to 61.32% in 2021. The trend analysis indicated an average annual decrease of 1.5% in polio vaccine coverage in Brazil. Across the country, 17 states showed a statistically significant reduction in the average annual percentage change rate. The highest average reduction rates in vaccine coverage among Brazilian states were observed in Amapá (−3.7%; 95%CI −6.0; −1.4) and Pernambuco (−3.3%; 95%CI −4.0; −2.5). In the spatial analysis, in Moran Global, a positive autocorrelation was identified in the years 2012 to 2021 (p<0.02), with an index value of 0.361, which means that geographically close areas tended to have similar levels of vaccination coverage. Conclusion: There was significant heterogeneity in coverage among states and a strong decrease trend in vaccination rates, which could facilitate the circulation of the poliovirus and pose a threat to the susceptible population.

RESUMO Objetivo: Analisar a distribuição temporal e espacial da cobertura da vacina contra poliomielite nos estados brasileiros. Métodos: Estudo ecológico de séries temporais, cuja fonte de dados foi o Sistema de Informação do Programa Nacional de Imunizações. O período analisado foi de 1997 a 2021. Utilizou-se o software Joinpoint para calcular a variação percentual anual e variação percentual anual média por meio de regressões. Para construção de mapas temáticos foi utilizado o software QGis 3.10.7. Para estimar a autocorrelação espacial com o Índice de Moran Global e Índice de Moran Local foi utilizado o software GeoDa 1.20.0.10. Resultados: A cobertura vacinal nacional em 1997 foi de 89,27%, passando para 61,32% em 2021. A análise de tendência apontou o decréscimo médio de 1,5% ao ano na cobertura da vacina contra poliomielite no Brasil. Em todo o país, 17 estados apresentaram redução estatisticamente significativa na taxa de variação percentual anual média. As maiores taxas médias de redução da cobertura vacinal entre os estados brasileiros foram observadas no Amapá (−3,7%; IC95% −6,0; −1,4) e em Pernambuco (−3,3%; IC95% −4,0; −2,5). Na análise espacial, no Moran Global, foi identificada autocorrelação positiva nos anos de 2012 a 2021 (p<0,02), com valor de índice de 0,361, o que significa que as áreas geograficamente próximas tenderam a ter níveis semelhantes de cobertura vacinal. Conclusão: Evidenciou-se expressiva heterogeneidade na cobertura entre os estados e forte tendência de queda dos índices, o que pode propiciar a circulação do poliovírus e colocar sob ameaça a população susceptível.

The role of a genetically stable, novel oral type 2 poliovirus vaccine in the poliomyelitis endgame / Utilidad de una nueva vacuna antipoliomielítica oral del serotipo 2 genéticamente estable contra el poliovirus de tipo 2 en la erradicación de la poliomielitis / O papel de uma nova vacina oral contra o poliovírus tipo 2, geneticamente estável, no estágio final da eliminação da poliomielite

ABSTRACT Poliovirus infection causes paralysis in up to 1 in 200 infected persons. The use of safe and effective inactivated poliovirus vaccines and live attenuated oral poliovirus vaccines (OPVs) means that only two pockets of wild-type poliovirus type 1 remain, in Afghanistan and Pakistan. However, OPVs can revert to virulence, causing outbreaks of circulating vaccine-derived poliovirus (cVDPV). During 2020-2022, cVDPV type 2 (cVDPV2) was responsible for 97-99% of poliomyelitis cases, mainly in Africa. Between January and August 2022, cVDPV2 was detected in sewage samples in Israel, the United Kingdom and the United States of America, where a case of acute flaccid paralysis caused by cVDPV2 also occurred. The Pan American Health Organization has warned that Brazil, the Dominican Republic, Haiti and Peru are at very high risk for the reintroduction of poliovirus and an additional eight countries in Latin America are at high risk, following dropping vaccination rates (average 80% coverage in 2022). Sabin type 2 monovalent OPV has been used to control VDPV2 outbreaks, but its use could also lead to outbreaks. To address this issue, a more genetically stable, novel OPV2 (nOPV2) was developed against cVDPV2 and in 2020 was granted World Health Organization Emergency Use Listing. Rolling out a novel vaccine under the Emergency Use Listing in mass settings to contain outbreaks requires unique local regulatory and operational preparedness.

RESUMEN La infección por poliovirus ocasiona parálisis en hasta 1 de cada 200 personas infectadas. La utilización de vacunas con poliovirus inactivados y de vacunas antipoliomielíticas orales con poliovirus vivos atenuados (OPV) seguras y eficaces ha logrado que solo queden dos focos de poliovirus salvaje de tipo 1, en Afganistán y Pakistán. Sin embargo, las vacunas con OPV pueden revertir a la virulencia y producir brotes de poliovirus circulantes de origen vacunal (cVDPV). Durante el período 2020-2022, el cVDPV de tipo 2 (cVDPV2) fue la causa del 97-99% de los casos de poliomielitis, sobre todo en África. Entre enero y agosto del 2022, se encontró el cVDPV2 en muestras de aguas residuales en Estados Unidos de América, donde se produjo un caso de parálisis flácida aguda por el cVDPV2, Israel y Reino Unido y. La Organización Panamericana de la Salud ha advertido que, tras la caída de las tasas de vacunación (con una cobertura promedio del 80% en el 2022), Brasil, Haití, Perú y República Dominicana corren un riesgo muy alto de reintroducción del poliovirus, en tanto que otros ocho países de América Latina se encuentran en una situación de alto riesgo. La OPV monovalente de tipo 2 de Sabin se ha utilizado para controlar los brotes de VDPV2, pero su empleo también podría ocasionar brotes. Para hacer frente a este problema, se creó una nueva OPV2 (nOPV2) contra el cVDPV2, genéticamente más estable, que en el 2020 se incluyó en la lista de uso en emergencias de la Organización Mundial de la Salud. El despliegue a gran escala de una nueva vacuna incluida en la lista de uso en emergencias con el fin de contener los brotes exige una extraordinaria preparación regulatoria y operativa local.

RESUMO A infecção pelo poliovírus causa paralisia em 1 de cada 200 pessoas infectadas. O uso de vacinas seguras e eficazes, tanto vacinas inativadas contra o poliovírus quanto vacinas orais contendo poliovírus atenuado (VOP), significa que restam apenas dois bolsões de poliovírus selvagem tipo 1, um no Afeganistão e outro no Paquistão. No entanto, a VOP pode reverter à virulência, causando surtos de poliovírus circulante derivado de vacina (cPVDV). No período 2020-2022, o cPVDV tipo 2 (cPVDV2) foi responsável por 97% a 99% dos casos de poliomielite, principalmente na África. Entre janeiro e agosto de 2022, o cPVDV2 foi detectado em amostras de esgoto em Israel, no Reino Unido e nos Estados Unidos da América, onde também houve um caso de paralisia flácida aguda causada pelo cPVDV2. A Organização Pan-Americana da Saúde alertou que, devido à queda nas taxas de vacinação (cobertura média de 80% em 2022), o Brasil, o Haiti, o Peru e a República Dominicana correm um risco muito alto de reintrodução do poliovírus e outros oito países da América Latina correm um risco alto. A VOP monovalente Sabin tipo 2 tem sido usada para controlar surtos de PVDV2, mas seu uso também pode levar a surtos. Para resolver esse problema, foi desenvolvida uma nova VOP2 (nVOP2), mais estável geneticamente, para combater o cPVDV2. Em 2020, a nVOP2 entrou na Lista de Uso Emergencial da Organização Mundial da Saúde. A distribuição de uma nova vacina incluída na Lista de Uso Emergencial em contextos de massa para conter surtos requer medidas originais de preparação operacional e regulatória em âmbito local.

An epidemiological investigation on vaccine-hypervariable poliovirus in a case with acute flaccid paralysis in Zhejiang Province / 预防医学

Abstract@#Vaccine-hypervariable poliovirus type Ⅲ was detected in an acute flaccid paralysis infant at age of 6 months in Zhejiang Province in June, 2021, and the isolated and incubated virus had six nucleotide variations in the VP1 region as compared to the poliovirus Sabin vaccine strain. The infant had a history of three-dose poliovirus vaccination, and grade 2 muscle strength of the left upper limb upon onset. He was clinically diagnosed with cellulitis of the left shoulder, and recovered to normal following treatment. No abnormality was detected in the nervous system, and the infant was cured and discharged from hospital. No vaccine-hypervariable poliovirus was detected in subsequent infant' clinical samples or in close contacts, and no similar cases were identified during the active case detection by county/district medical institutions and among community populations. Since the infant did not present poliomyelitis-related clinical symptoms caused by vaccine-hypervariable poliovirus, poliomyelitis was excluded. The vaccine-hypervariable poliovirus was not spread because of timely identification and effective responses, suggesting the urgent need to maintain the sensitivity of the acute flaccid paralysis surveillance system and improve the coverage of poliovirus vaccination, so as to inhibit the transmission of poliovirus.

Effect of multiple punctures on quality of inactivated poliomyelitis vaccine made from Sabin strains in 5-dose vial presentation / 中国生物制品学杂志

@#ObjectiveTo evaluate the effect of multiple punctures on the quality of inactivated poliomyelitis vaccine made from Sabin strains(sIPV)in 5-dose vials.MethodsPre-puncture samples were sampled by opening the cover from 3batches of sIPV stored for about 24 months and balanced at room temperature at least 20 min;The same three batches of sIPV were punctured for the first to fifth needle on the 0,7,14,21 and 28 d respectively,which were balanced at room temperature at least 20 min before each sampling. After sampling,the remaining samples were returned to 2～8 ℃ for preservation. According to the requirements of enterprise registration standard(YBS01052021),all the samples before and after the fifth needle puncture were tested,and the other 4 needle puncture samples were tested for pH,osmotic molar concentration,aseptic test,bacterial endotoxin,D antigen content of typeⅠ,Ⅱ and Ⅲ virus,appearance,abnormal toxicity,protein content and 2-phenoxyethanol content. The relative change rates of 2-phenoxyethanol content,protein content,osmotic molar concentration and D antigen content of typeⅠ,Ⅱ and Ⅲ virus were calculated. SPSS 20 software was used to analyze the relative change rate of each index by one-way ANOVA,and the effect of multiple punctures on the quality of sIPV was evaluated.ResultsThe result of each test item was in compliance with enterprise registration standard before and after each puncture. There was no significant difference between each puncture on the relative rate of change of 2-phenoxyethanol content,protein content,D-antigen content of typeⅡ and Ⅲ virus(F = 2. 125,1. 155,1. 137 and 1. 882,P = 0. 152,0. 386,0. 393and 0. 190,respectively);There was a significant difference in the relative change rate of osmotic molar concentration and Dantigen content of TypeⅠvirus(F = 4. 750 and 4. 010,P = 0. 021 and 0. 034,respectively). The result of Duncan test showed that compared with the first puncture,the relative change rate of osmotic molar concentration after the second and third puncture showed no significant difference,while that after the fourth puncture showed significant difference and a relatively stable result was observed after the fifth puncture. Regarding the relative rate of change of D-antigen content of TypeⅠvirus,there was no significant difference among the first,second,fourth and fifth punctures,while a significant difference existed between the third and the other four punctures.ConclusionFive punctures within 28 days had no effect on the quality of sIPV in 5-dose vials.

Quality evaluation of inactivated poliomyelitis vaccine made from Sabin strains after optimization / 中国生物制品学杂志

@#Objective To evaluate the product quality of inactivated poliomyelitis vaccine made from Sabin strains(sIPV)after optimization of preparation formula.Methods The quality attributes of sIPV products after preparation optimization(no phenol red and no bacteriostatic agent)were evaluated,and the quality comparability with the listed sIPV products was analyzed;270 Wister rats of half male and half female were immunized with the finished products before and after preparation optimization simultaneously by intramuscular injection,measured for the level of neutralizing antibody in serum,evaluated for the immunogenicity,and analyzed for the compa-rability;The finished products with optimized preparation were placed at 37 ℃,room temperature(20～25 ℃)and 2～8 ℃ for accelerated and long-term stability tests separately,detected for the content of key indicator D antigen to evaluate the stability,and analyzed for the comparability with historical data of the listed products.Results After preparation formula optimization,the detection results of the sIPV vaccine for typeⅠ,Ⅱ,and Ⅲ D antigen content,protein content,pH value,Vero cell protein residue,bovine serum albumin residue,Vero cell DNA residue,and free formaldehyde content all conformed to the requirements of Chinese Pharmacopoeia Ⅲ (2020 edition)and the enterprise standard. Before and after the process optimization,the quality attributes,immunogenicity and accelerated and long-term stability trends were consi-stent.Conclusion The formulation of the optimized sIPV vaccine no longer contains phenol red and bacteriostatic agent ingredients,of which the safety has been improved;The quality attributes,immunogenicity,and stability of the product are highly similar to those before optimization;All indicators met the requirements during the validity period and the product has good stability.

Declaración SLIPE: Aumento de la cobertura antipoliomielítica con vacunas más seguras: una urgencia inaplazable en Latinoamérica

Ante el riesgo real de ocurrencia de brotes de parálisis fláccida aguda en la región debidos a poliovirus derivado de la vacuna Sabin o a la importación de poliovirus salvaje, la Sociedad Latinoamericana de Infectología Pediátrica comisionó a un grupo ad hoc de expertos integrantes del Comité de Vacunas y Biológicos de la institución, para redactar un documento oficial de posición sobre la necesidad imperiosa de incrementar los niveles de inmunización contra la enfermedad en la región e incorporar definitivamente en forma exclusiva la vacuna de polio inactivada en todos los esquemas nacionales de vacunación. La presente publicación discute las principales conclusiones y recomendaciones generadas como resultado de esta actividad.

Given the actual risk of poliomyelitis outbreaks in the region due to poliovirus derived from the Sabin vaccine or the importation of wild poliovirus, the Latin American Society of Pediatric Infectious Diseases commissioned an ad hoc group of experts from the institution's Vaccines and Biologicals Committee, to draft an official position paper on the urgent need to increase immunization levels against the disease in the region and incorporate inactivated polio vaccine exclusive schedules in all national immunization programs. This publication discusses the main conclusions and recommendations generated as a result of such activity.

Increasing polio coverage with safer vaccines: a pressing need in Latin America

Given the actual risk of poliomyelitis outbreaks in the region due to poliovirus derived from the Sabin vaccine or the importation of wild poliovirus, the Latin American Society of Pediatric Infectious Diseases commissioned an ad hoc group of experts from the institution's Vaccines and Biologicals Committee, to draft an official position paper on the urgent need to increase immunization levels against the disease in the region and incorporate inactivated polio vaccine exclusive schedules in all national immunization programs. This publication discusses the main conclusions and recommendations generated as a result of such activity.

Ante el riesgo real de ocurrencia de brotes de parálisis fláccida aguda en la región debidos a poliovirus derivado de la vacuna Sabin o a la importación de poliovirus salvaje, la Sociedad Latinoamericana de Infectología Pediátrica comisionó a un grupo ad hoc de expertos integrantes del Comité de Vacunas y Biológicos de la institución, para redactar un documento oficial de posición sobre la necesidad imperiosa de incrementar los niveles de inmunización contra la enfermedad en la región e incorporar definitivamente en forma exclusiva la vacuna de polio inactivada en todos los esquemas nacionales de vacunación. La presente publicación discute las principales conclusiones y recomendaciones generadas como resultado de esta actividad.

The Surgical Challenges of Intertrochanteric Hip Fracture in a Patient with Polio Dysplastic Hip and Previous Distal Femur Fracture: A Case Report

@#Poliomyelitis is on the verge of eradication since the introduction of the vaccine in 1950. In developed countries, those afflicted with the disease are primarily in their sixth decade and beyond, usually with disabling complications. Due to the diminished muscle power coupled with the abnormal bony anatomy and joint contractures, patients with polio present unique surgical challenges when they sustain fragility fractures. We report an uncommon case of intertrochanteric hip fracture in a limb affected with polio and hip dysplasia, on a background of ipsilateral distal femur fracture with previous surgical fixation. We aim to outline the challenges encountered during the surgery and the preoperative planning to overcome these shortcomings.

Aspectos históricos, clínicos y epidemiológicos de la poliomielitis en México (1946 - 1960) / Historical, clinical and epidemiological aspects of poliomyelitis in Mexico (1946-1960)

La poliomielitis emergió en Europa como enfermedad epidémica a finales del siglo XIX. Durante los años treinta del siglo XX alcanzó gran intensidad en los Estados Unidos y Canadá, pero fue tras la Segunda Guerra Mundial cuando la enfermedad se convirtió en un grave problema de salud pública mundial que castigó terriblemente a varios países del mundo, incluyendo a México. La poliomielitis es una enfermedad viral muy contagiosa que invade el sistema nervioso central (destruye las neuronas motoras) que atemorizó a la población mexicana en la primera mitad del siglo XX, no tanto por las altas cifras de mortalidad y morbilidad sino por sus secuelas paralíticas, como la invalidez, y por el hecho de que afectó a uno de los grupos poblacionales más vulnerables: los niños. La enfermedad afectaba principalmente a los niños menores de cinco años, siendo poco frecuente en los primeros meses de vida del recién nacido debido al efecto protector de la inmunidad que le transfiere la madre al hijo a través de la leche materna; después de ocho meses, al término de la alimentación, el infante podía ser infectado por el poliovirus invadiendo la medula espinal y produciendo la parálisis, más comúnmente de las piernas o tronco. Asimismo, ocasionaba una parálisis en los músculos respiratorios (diafragma) de los niños, a quienes había que auxiliarlos a respirar ya que, si no, se asfixiaban, por lo que se les introducía en unas máquinas conocidas comúnmente como pulmones de acero o pulmotores de tipo Emerson (máquina que permite a una persona respirar cuando esta perdió el control de sus músculos respiratorios, como el diafragma, inventada en 1928 por el ingeniero estadounidense Philip Drinker).

Poliomyelitis emerged in Europe as an epidemic disease at the end of the 19th century. During the thirties of the twentieth century it reached great intensity in the United States and Canada, but it was after the Second World War when the disease became a serious world public health problem, which punished several countries of the world, including Mexico. Poliomyelitis is a very contagious viral disease that invades the central nervous system (destroys motor neurons) that frightened the Mexican population in the first half of the twentieth century, not so much by high mortality and morbidity figures but by its paralytic sequels, like the disability, and by the fact that it affected one of the most vulnerable population groups: children. The disease mainly affected children under five years of age, being rare in the first months of life of the newborn due to the protective effect of immunity that the mother transfers to the son through breast milk; After eight months, at the end of the feed, the infant could be infected by poliovirus by invading the spinal cord and producing paralysis, most commonly of the legs or trunk. Likewise, it caused a paralysis in the respiratory muscles (diaphragm) of children, who had to help them to breathe since, if not, they were suffocated, so they were introduced in machines commonly known as steel lungs or lungs of Emerson type (machine that allows a person to breathe when he lost control of his respiratory muscles, such as the diaphragm, invented in 1928 by the American engineer Philip Drinker).

La pandemia que atacó a los chicos: el Hospital Infantil de México Federico Gómez en la lucha contra la poliomielitis en México (1943-1950) / The pandemic that struck the boys: the Hospital Infantil de México Federico Gómez in the fight against poliomyelitis in Mexico (1943-1950)

Resumen Se describe cómo se articuló la lucha contra la poliomielitis y las secuelas que dejaba la enfermedad en el Hospital Infantil de México Federico Gómez. Se narra cómo dicha lucha exigió que algunos ortopedistas, como Alfonso Tohen Zamudio, Alejandro Velasco Zimbrón, Juan Farill y Luis Sierra Rojas, aplicaran técnicas quirúrgicas ideadas por ellos y se diera la invención de aparatos ortopédicos que ocuparon un lugar fundamental en la estrategia terapéutica de la poliomielitis al preservar la marcha segura, prevenir o disminuir deformidades y reducir la fatiga. El hospital no tardó en convertirse en el centro de concentración obligado y único para los niños enfermos de poliomielitis procedentes de todo el país, al crear una sala para atender los casos agudos.

Abstract This article studies how the fight against poliomyelitis and the sequelae left by the disease was articulated in the Hospital Infantil de México Federico Gómez and shows how this fight required some orthopedists, such as Alfonso Tohen Zamudio, Alejandro Velasco Zimbrón, Juan Farill, and Luis Sierra Rojas, to apply surgical techniques devised by them, as well as the invention of orthopedic devices that occupied a fundamental place in the therapeutic strategy of poliomyelitis by preserving a safe gait, avoiding falls, preventing or reducing deformities, and reducing fatigue. The hospital soon became the obligatory and only concentration center for children with polio from all over the country by creating a ward to attend to acute cases.

Análisis biomecánico de la marcha en paciente con secuelas de poliomielitis y artroplastia de rodilla / Análise biomecânica da marcha em um paciente com sequelas de poliomielite e artroplastia do joelho / Clinical gait analysis in patient with poliomyelitis sequelae and total knee arthroplasty

Resumen: La poliomielitis es una enfermedad que puede provocar secuelas irreversibles, generando pérdida de fuerza muscular, parálisis e hiporreflexia, entre otras. Hoy en día las infecciones por poliovirus están controladas, pero se siguen tratando personas con secuelas que pueden ver afectada su calidad de vida y funciones cotidianas, tales como la marcha. Habiendo agotado las opciones de tratamiento conservadoras, la artroplastia total de rodilla (ATR) es una de las intervenciones quirúrgicas más habituales cuando las secuelas afectan la morfología y funcionalidad de dicha articulación. El objetivo del estudio es realizar un análisis instrumentado de la marcha de un paciente con secuelas de poliomielitis y una ATR, con el fin de definir las mejores estrategias de rehabilitación y mejorar la recuperación de la máxima funcionalidad. El estudio se realizó en un Laboratorio de Análisis de Movimiento con 8 cámaras, mediante la colocación de marcadores reflectivos en el cuerpo del paciente. Los resultados muestran alteraciones del patrón de marcha en todas las articulaciones de las extremidades inferiores y en cada uno de los planos anatómicos, siendo la más relevante la rotación interna de la articulación de la cadera derecha y una flexión fija en 9 ° de la articulación de la rodilla ipsilateral, durante la primera mitad del ciclo de marcha. El análisis sugiere que el paciente adopta estrategias que favorecen la activación del tensor de la fascia lata como flexor de cadera y estabilizador de la articulación de la rodilla en la máxima extensión disponible (9 ° de flexión), en sustitución del músculo cuádriceps, debilitado debido a las secuelas de la poliomielitis.

Resumo: A poliomielite é uma doença que pode causar sequelas irreversíveis, causando perda de força muscular, paralisia e hiporreflexia, entre outras. Hoje as infecções por poliovírus são controladas, mas ainda existen pessoas en tratamento pelas sequelas que podem danificar sua qualidade de vida e funções diárias, como caminhar. Esgotadas as opções de tratamento conservador, a artroplastia total do joelho (ATJ) é uma das intervenções cirúrgicas mais comuns quando as sequelas afetam a morfologia e a funcionalidade dessa articulação. O objetivo deste trabalho é realizar uma análise instrumentada da marcha de um paciente com sequela de poliomielite e ATJ, a fim de definir as melhores estratégias de reabilitação e melhorar a recuperação da funcionalidade máxima. O estudo foi realizado em um Laboratório de Análise de Movimento com 8 câmeras, por meio da colocação de marcadores reflexivos no corpo do paciente. Os resultados mostram alterações no padrão de marcha em todas as articulações dos membros inferiores e em cada um dos planos anatômicos, sendo as mais relevantes a rotação interna do quadril direito e a flexão fixa do joelho ipsilateral a 9 ° durante o primeiro ciclo do meio da marcha. A análise sugere que o paciente adote estratégias que favoreçam a ativação do tensor da fáscia lata como flexor do quadril e estabilizador do joelho na extensão máxima disponível (9 ° de flexão), substituindo o músculo quadríceps, enfraquecido pelas sequelas de poliomielite.

Abstract: Poliomyelitis is a disease that may cause irreversible sequelae, generating muscle strength deficits, flaccid paralysis and hyporeflexia, among others. Even though poliovirus infections are under control, people with sequelae that can affect their quality of life and everyday functions such as walking, are still being treated. When these sequelae affect the morphology and functionality of the knee joint, and every other conservative option has been exhausted, the total knee arthroplasty (TKA) is one of the most common surgical interventions. The main goal of the present study is to perform an instrumented gait analysis test of a patient with poliomyelitis sequelae and TKA, in order to define the best rehabilitation strategy and achieve the highest level possible of the patient's function. 3D Gait Analysis was performed with an 8-camera motion capture system and reflective markers placed on specific body landmarks. Results show gait pattern disturbances in every joint and at every anatomical plane, being the most relevant the right hip internal rotation and a fixed 9 degrees ipsilateral knee flexion during the first half of the gait cycle. The analysis suggests that the patient adopts strategies that promote the activation of the tensor fascia lata as hip flexor and knee stabilizer at the maximum available extension (9 ° of flexion) replacing the weakened quadriceps muscle due to the poliomyelitis sequelae.

Knowledge of healthcare professionals about poliomyelitis and postpoliomyelitis: a cross-sectional study

ABSTRACT BACKGROUND: Postpoliomyelitis syndrome is a clinical condition that can affect poliomyelitis survivors. OBJECTIVE: Our aim was to evaluate knowledge of poliomyelitis and postpoliomyelitis syndrome among Brazilian healthcare professionals. DESIGN AND SETTING: Cross-sectional study conducted at a Brazilian public higher education institution located in the state of Goiás. METHODS: The participants (n = 578) were Brazilian physicians, physical therapists, nurses, nutritionists and psychologists. A self-administered questionnaire (30 questions) was designed to probe knowledge about poliomyelitis and postpoliomyelitis syndrome. From the questionnaire, we created a structured test to objectively evaluate the knowledge of these professionals. The test was composed of 20 questions and was scored over a range from 0 (totally ill-informed) to 20 (totally well-informed). RESULTS: In general, the physicians, physical therapists and nurses demonstrated better understanding of poliomyelitis and postpoliomyelitis syndrome. The healthcare professionals who had received previous information about poliomyelitis and postpoliomyelitis syndrome had significantly higher scores than those who had never received information (P < 0.001). On average, this difference was approximately 28.6%. CONCLUSIONS: The findings from the present study indicate that there is a critical need for improvement of knowledge about postpoliomyelitis syndrome among Brazilian healthcare professionals. The services provided by these professionals may therefore become compromised. Furthermore, public healthcare initiatives should be implemented to improve knowledge among healthcare professionals.

Poliomielitis, una historia de inicio triste y final feliz / Poliomyelitis, a story with a sad beginning and a happy ending

Se desarrollan los principales elementos históricos en el estudio y la lucha contra la poliomielitis, su aislamiento por Karl Landsteiner en 1909, la primera vacuna con virus muerto (Jonas Salk, 1955), la segunda vacuna con virus vivo atenuado (Albert Sabin, 1961) y la reducción paulatina de la polio en todo el mundo, hasta llegar a menos de 200 casos al año (virus salvaje)(AU)

The main historical events in the study and fight against polio are shown, its isolation by Karl Landsteiner in 1909, the development of the first vaccine with dead virus (Jonas Salk, 1955), the second vaccine with live attenuated virus (Albert Sabin, 1961) and the gradual reduction of polio worldwide, reaching less than 200 cases a year (wild virus)(AU)

Prevalence of neutralizing antibodies against poliovirus 1, 2, and 3 in healthcare professionals aged 20-50 years / Prevalência de anticorpos neutralizantes contra poliovírus 1, 2 e 3 em profissionais de saúde de 20 a 50 anos de idade

ABSTRACT Objective: To describe the prevalence of neutralizing antibodies against poliovirus (PV1, PV2, and PV3) in blood samples of healthcare professionals aged 20 to 50 years. Methods: Health professionals who serve children at Darcy Vargas Children's Hospital and the Department of Pediatrics of Irmandade da Santa Casa de São Paulo. The sample size was calculated at 323 participants. The Mantel-Haenszel chi-square was used to verify differences between groups. The neutralization reaction detected human poliovirus antibodies. For susceptible individuals, vaccination with the inactivated+triple acellular polio vaccine was performed, and neutralizing antibodies were re-dosed after one week. Results: 333 professionals were studied - 92.8% were immune to poliovirus 1, 86.5% to poliovirus 2, and 63.3% to poliovirus 3; 37% had titers less than 1:8 for any serotype, 5;1% had titers below 1:8 for all three. Vaccination with inactivated polio vaccine was performed for susceptible participants, and neutralizing antibodies were dosed after one week, showing increased titers for all polioviruses. Conclusions: Despite the detection of a significant percentage of individuals with low poliovirus antibody titer, the challenge with vaccination demonstrated immune response compatible with poliovirus immunity.

RESUMO Objetivo: Descrever a prevalência de anticorpos neutralizantes contra poliovírus (tipos 1, 2 e 3) em amostra de sangue de profissionais de saúde com idade de 20 a 50 anos. Métodos: Profissionais de saúde que atendem crianças do Hospital Infantil Darcy Vargas e do Departamento de Pediatria da Irmandade da Santa Casa de São Paulo. O tamanho da amostra foi de 323 participantes. Os anticorpos contra poliovírus humanos foram detectados pela reação de neutralização. Para os indivíduos suscetíveis, foram administradas vacina para poliomielite inativada+tríplice e nova dosagem de anticorpos neutralizantes após uma semana. Utilizou-se o teste do qui-quadrado de Mantel-Haenszel para verificar as diferenças entre os grupos. Resultados: Foram estudados 333 profissionais - 92,8% eram imunes ao poliovírus 1; 86,5%, ao poliovírus 2; 63,57%, ao poliovírus 3; 37% apresentaram títulos inferiores a 1:8 para qualquer sorotipo; 5,1% tinham títulos abaixo de 1:8 para os três. Após a vacinação dos suscetíveis, houve elevação dos títulos para todos os poliovírus. Conclusões: Apesar da detecção de percentual significativo de indivíduos com baixo título de anticorpos para poliovírus, o desafio da vacinação demonstrou resposta imune robusta compatível.

Attitude and perception towards vaccination against poliomyelitis in Peshawar, Pakistan

ABSTRACT OBJECTIVE: This research aimed to quantitatively assess the general public's awareness, attitude and perception of polio and its vaccination in Peshawar KPK, Pakistan. METHODS: We conducted a survey-based study to understand the surge in polio cases from 2015 to 2019 in the Peshawar city of the Khyber Pakhtunkhwa (KPK), Pakistan. A pre-tested questionnaire-based study was conducted in 2019 to assess the attitude and general perception of residents of Peshawar KPK towards polio vaccination. RESULTS: Out of 241 country-wide polio cases, 63 (26.1%) polio cases were reported in Peshawar city from 2015-2019. The questionnaire revealed that individuals between 18-30 years of age had sufficient knowledge (65.1%) about polio. Male and female participants had equal awareness (~ 43%). Participants with higher education (45.9%), those with better financial status (49.5%), individuals with children < 5 years of age (46.4%), and those who had experience of a polio patient (63.1%) had better knowledge. Participants inhabiting the central city were better aware (50.5%) of polio than individuals living in the outskirts. CONCLUSION: The data indicated that poor knowledge and negative attitudes of people towards polio vaccination are the main causes of the polio eradication program's failure. Moreover, religious beliefs, unchecked migration between the Pak-Afghan border, and lack of knowledge about polio vaccination are identified as critical barriers to polio eradication.

Current polio status in the world / Estado atual de poliomielite no mundo

ABSTRACT Poliomyelitis is still an endemic disease in Afghanistan, Nigeria, and Pakistan despite the efforts to eradicate the disease. Therefore, there is a potential risk of international spread. Since the start of the polio eradication program by the Global Polio Eradication Initiative in 1988, the incidence of polio has been reduced by 99%. In the last decade, wild poliovirus type 2 (WPV2) was eliminated and declared eradicated in 2015. Wild poliovirus type 3 (WPV3) was last reported in November 2012. These changes have allowed the removal of Sabin poliovirus type 2 from the oral poliovirus vaccine (OPV) in April 2016 and countries either introduced bivalent OPV (bOPV) containing Sabin types 1 + 3 poliovirus or added at least one dose of inactivated poliovirus vaccine (IPV) into their routine immunization schedule. Many efforts are needed to eradicate polio, and new strategies should be implemented such as the development and approval of new genetically stable OPV, and vaccines that do not require infectious processes for virus growth, such as virus-like particles (VLPs), or packing-cell technology. IPV will increasingly be produced from Sabin strains, and further attenuated or genetically modified strains. Furthermore, there is also a need for the development of antiviral drugs to treat immunodeficient patients who are long-term excretors infected with poliovirus, thus avoiding contamination of individuals susceptible to polioviruses, due to reversal of pathogenicity. If all these measures are successfully implemented, the world will be close to the global

RESUMEN La poliomielitis sigue siendo una enfermedad endémica en Afganistán, Nigeria y Pakistán a pesar de los esfuerzos por erradicar la enfermedad. Por lo tanto, existe un riesgo de propagación mundial. Desde el inicio del programa de erradicación de la poliomielitis por la Iniciativa de Erradicación Mundial de la Poliomielitis [Global Polio Eradication Initiative (GPEI)] en 1988, la incidencia de la poliomielitis se ha reducido en un 99%. En la última década, el poliovirus salvaje tipo 2 (WPV2) fue eliminado y declarado erradicado en 2015. El poliovirus salvaje tipo 3 (WPV3) se informó por última vez en noviembre de 2012. Estos cambios han permitido la eliminación del poliovirus Sabin tipo 2 de la vacuna antipoliomielítica oral (VPO) en abril de 2016, y los países introdujeron la VPO de tipo bivalente (bVPO), que contiene poliovirus Sabin tipos 1 y 3, o agregaron al menos una dosis de vacuna antipoliomielítica inactivada (VPI) al programa de inmunización de rutina. Se necesitan muchos esfuerzos para erradicar la poliomielitis y se deben implementar nuevas estrategias, como el desarrollo y aprobación de nuevas VPO genéticamente estables y vacunas que no requieren procesos infecciosos para el crecimiento del virus, como partículas pseudovirales (VLP) o tecnología de células empaquetadas (packing-cell). La VIP se producirá cada vez más a partir de cepas Sabin y otras cepas más atenuadas o modificadas genéticamente. Además, también es necesario desarrollar fármacos antivirales para tratar a pacientes inmunodeficientes que son excretores a largo plazo, evitando así la contaminación de individuos susceptibles a poliovirus, debido a la reversión de la patogenicidad. Si todas estas medidas se implementan con éxito, el mundo estará cerca de la interrupción global de la transmisión del WPV y la erradicación de la poliomielitis.

RESUMO A poliomielite ainda é uma doença endêmica no Afeganistão, na Nigéria e no Paquistão, apesar dos esforços para erradicá-la. Portanto, há risco de propagação mundial. Desde o início do programa de erradicação da poliomielite pela Iniciativa de Erradicação Global da Pólio [Global Polio Eradication Initiative (GPEI)], em 1988, a incidência da doença foi reduzida em 99%. Na última década, o poliovírus selvagem do tipo 2 (WPV2) foi eliminado e declarado erradicado em 2015. O poliovírus selvagem do tipo 3 (WPV3) foi reportado pela última vez em novembro de 2012. Essas mudanças promoveram a remoção do poliovírus Sabin tipo 2 da vacina oral antipólio (VOP) em abril de 2016, e os países introduziram a vacina oral bivalente (VOPb), que contém os poliovírus Sabin tipos 1 + 3, ou adicionaram pelo menos uma dose da vacina inativada contra o poliovírus (VIP) no calendário de imunização. É necessário muito empenho para erradicar a poliomielite. Novas estratégias devem ser implementadas, como o desenvolvimento e a aprovação de novas VOPs geneticamente estáveis e vacinas que não requerem processos infecciosos para o crescimento do vírus, como partículas pseudovirais (VLP), ou tecnologia de células de empacotamento (packing-cell). A VIP será cada vez mais produzida a partir de cepas Sabin, de outras cepas atenuadas ou geneticamente modificadas. Além disso, é imprescindível o desenvolvimento de medicamentos antivirais para tratar os pacientes imunodeficientes que são excretores de longo prazo, evitando assim a contaminação de indivíduos suscetíveis aos poliovírus, devido à reversão da patogenicidade. Se todas essas medidas forem implementadas com sucesso, o mundo estará próximo da interrupção global de transmissão do WPV e da erradicação da poliomielite.

Poliomielitis en Argentina: epidemias, políticas sanitarias, tratamientos e instituciones / Poliomyelitis in Argentina: epidemics, public health policies, treatments and institutions

RESUMEN El presente artículo tiene como finalidad historiar las epidemias de poliomielitis sufridas en Argentina en el transcurso del siglo XX. Se describen sus consecuencias médicas, las políticas llevadas a cabo por los distintos gobiernos para enfrentarlas, la reacción de la sociedad frente a la amenaza de la enfermedad, los diversos trámites efectuados para conseguir la vacuna y su aplicación a la comunidad. Dado que la poliomielitis es una enfermedad capaz de dejar secuelas invalidantes, la segunda parte de este estudio analiza las diferentes entidades y medidas, oficiales y privadas, que se abocaron a la rehabilitación de los pacientes.

ABSTRACT The purpose of this article is to record the polio epidemics suffered in Argentina during the 20th century. It describes the medical consequences, the policies carried out by the different governments to confront them, the reaction of society to the threat of the disease, the various procedures performed to obtain the vaccine and its application to community Since poliomyelitis is a disease capable of leaving disabling sequelae, the second part of this study analyzes the different entities along with public and private measures that were taken for the rehabilitation of patients.

A erradicação da poliomielite em quatro tempos / La erradicación de la poliomielitis en cuatro tiempos / Poliomyelitis eradication in four stages

O objetivo deste artigo é rever o "estado da arte" dos avanços, obstáculos e estratégias para atingir a erradicação global da pólio. As ações de controle da poliomielite iniciaram na década de 1960 com o advento das duas vacinas antipoliomielíticas, a vacina oral da pólio (VOP) e a vacina inativada da pólio (VIP). No período de 1985 a 2020, são implementadas estratégias para atingir a meta de erradicação do poliovírus selvagem (WPV). Após o sucesso da interrupção da transmissão autóctone do WPV na região da Américas, foi lançada a meta da erradicação global. Descrevemos o processo de erradicação em quatro tempos: (1) O advento das vacinas VIP e VOP iniciou a era do controle da poliomielite; (2) A utilização massiva e simultânea da VOP teve impacto significativo sobre a transmissão do poliovírus selvagem no final da década de 1970 no Brasil; (3) Políticas públicas (nacionais e internacionais) decidem pela erradicação da transmissão autóctone do poliovírus selvagem nas Américas e definem as estratégias epidemiológicas para interromper a transmissão; e (4) A implantação das estratégias de erradicação interrompeu a transmissão autóctone do WPV em quase todas as regiões do mundo, exceto no Paquistão e Afeganistão, onde, em 2020, cadeias de transmissão do WPV1 desafiam as estratégias de contenção do vírus. Por outro lado, a persistência e a disseminação da circulação do poliovírus derivado da VOP, em países com baixa cobertura vacinal, somadas às dificuldades para substituir a VOP pela VIP constituem, atualmente, os obstáculos para a erradicação a curto prazo. Finalmente, discutimos as estratégias para superar os obstáculos e os desafios na era pós-erradicação.

El objetivo de este artículo es revisar el "estado de la cuestión" de los avances, obstáculos y estrategias para alcanzar la erradicación global de la polio. Las acciones de control de la poliomielitis se iniciaron en la década de 1960, con el advenimiento de las dos vacunas antipoliomielíticas, la vacuna oral de la polio (VOP) y la vacuna inactivada de la polio (VIP). En el período de 1985 a 2020, se implementan estrategias para alcanzar la meta de la erradicación del virus de la polio salvaje (WPV). Tras el éxito de la interrupción de la transmisión autóctona del WPV en la región de las Américas, se lanzó la meta de la erradicación global. Describimos el proceso de erradicación en cuatro tiempos: (1) El advenimiento de las vacunas VIP y VOP inició la era del control de la poliomielitis; (2) La utilización masiva y simultánea de la VOP tuvo un impacto significativo sobre la transmisión del virus de la polio salvaje, al final de la década de 1970, en Brasil; (3) Políticas públicas (nacionales e internacionales) deciden la erradicación de la transmisión autóctona del virus de la polio salvaje en las Américas y definen las estrategias epidemiológicas para interrumpir la transmisión; y (4) La implantación de las estrategias de erradicación interrumpió la transmisión autóctona del WPV en casi todas las regiones del mundo, excepto en Paquistán y Afganistán, donde, en 2020, cadenas de transmisión del WPV1 desafían las estrategias de contención del virus. Por otro lado, la persistencia y la diseminación de la circulación del virus de la polio, derivado de la VOP, en países con baja cobertura de vacunas, sumadas a las dificultades para substituir la VOP por la VIP constituyen, actualmente, los obstáculos para la erradicación a corto plazo. Finalmente, discutimos las estrategias para superar los obstáculos y los desafíos en la era poserradicación.

This article's objective is to review the "state of the art" in the progress, obstacles, and strategies for achieving global polio eradication. Poliomyelitis control measures began in the 1960s with the advent of two vaccines, the oral polio vaccine (OPV) and the inactivated polio vaccine (IPV). From 1985 to 2020, strategies were implemented to reach the goal of eradication of wild poliovirus (WPV). Following the success with the interruption of indigenous WPV transmission in the Americas, the goal of global eradication was launched. We describe the process of eradication in four historical stages: (1) The advent of the inactivated and oral polio vaccines launched the age of poliomyelitis control; (2) The massive and simultaneous use of OPV had a significant impact on WPV transmission in the late 1970s in Brazil; (3) Domestic and international public policies set the goal of eradication of indigenous WPV transmission in the Americas and defined the epidemiological strategies to interrupt transmission; and (4) The implementation of eradication strategies interrupted indigenous WPV transmission in nearly all regions of the world except Pakistan and Afghanistan, where in 2020 the WPV1 transmission chains have challenged the strategies for containment of the virus. Meanwhile, the persistence and dissemination of circulation of OPV-derived poliovirus in countries with low vaccination coverage, plus the difficulties in replacing OPV with IPV, are currently the obstacles to eradication in the short term. Finally, we discuss the strategies for overcoming the obstacles and challenges in the post-eradication era.